knowledge -WSS

knowledge

author：leisure time 2025-10-01 13:04:35 Page View：2654

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At ASCO, AstraZeneca reports strong data for breast cancer drug
Next article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

explore

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

A new House health package & hospitals’ new site

AlexHogan/STATYou’rereadingthewebeditionofD.C.Diagnosis. Signuphere toreceivethisnewsletterinyourinb

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

House transparency, PBM reform bill gains bipartisan support

Rep.FrankPallone(D-N.J.)J.ScottApplewhite/APWASHINGTON—ADemocrathassignedontoalegislativepackagethat